153 related articles for article (PubMed ID: 22639024)
1. [Chemoprevention of prostate cancer - a plea].
Schmitz-Dräger BJ; Bismarck E; Schöffski O; Fischer C
Aktuelle Urol; 2012 May; 43(3):157-61. PubMed ID: 22639024
[TBL] [Abstract][Full Text] [Related]
2. Risk adapted chemoprevention for prostate cancer: an option?
Schmitz-Dräger BJ; Schöffski O; Marberger M; Sahin S; Schmid HP
Recent Results Cancer Res; 2014; 202():79-91. PubMed ID: 24531781
[TBL] [Abstract][Full Text] [Related]
3. [Letter to P. Hammerer. chemoprevention of prostate cancer. Act Urol. 2012; 43].
Schmitz-Dräger BJ
Aktuelle Urol; 2013 Jan; 44(1):53. PubMed ID: 23381879
[No Abstract] [Full Text] [Related]
4. Chemoprevention of prostate cancer.
Vemana G; Hamilton RJ; Andriole GL; Freedland SJ
Annu Rev Med; 2014; 65():111-23. PubMed ID: 24188663
[TBL] [Abstract][Full Text] [Related]
5. [Chemoprevention of prostate cancer. Current status].
Schmitz-Dräger BJ; Lümmen G; Schäfer RM
Urologe A; 2007 Jun; 46(6):611-5. PubMed ID: 17483928
[TBL] [Abstract][Full Text] [Related]
6. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological approaches to reducing the risk of prostate cancer.
Rittmaster RS; Fleshner NE; Thompson IM
Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer: a serious disease suitable for prevention.
Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
[TBL] [Abstract][Full Text] [Related]
9. An update on chemoprevention strategies in prostate cancer for 2006.
Neill MG; Fleshner NE
Curr Opin Urol; 2006 May; 16(3):132-7. PubMed ID: 16679848
[TBL] [Abstract][Full Text] [Related]
10. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
11. What's wrong with chemoprevention of prostate cancer?
Justman S
Am J Bioeth; 2011 Dec; 11(12):21-5. PubMed ID: 22146025
[TBL] [Abstract][Full Text] [Related]
12. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R
N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880
[No Abstract] [Full Text] [Related]
13. Chemoprevention of prostate cancer.
Stephenson AJ; Abouassaly R; Klein EA
Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515
[TBL] [Abstract][Full Text] [Related]
14. Update on chemoprevention for prostate cancer.
Strope SA; Andriole GL
Curr Opin Urol; 2010 May; 20(3):194-7. PubMed ID: 20216317
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention using dutasteride: the REDUCE trial.
Gomella LG
Curr Opin Urol; 2005 Jan; 15(1):29-32. PubMed ID: 15586026
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer chemoprevention with 5α-reductase inhibitors.
Nepple KG; Andriole GL
Urol Oncol; 2012 Sep; 30(5):553-4. PubMed ID: 23193568
[No Abstract] [Full Text] [Related]
17. Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice.
Canby-Hagino ED; Thompson IM
Nat Clin Pract Oncol; 2005 May; 2(5):255-61. PubMed ID: 16264961
[TBL] [Abstract][Full Text] [Related]
18. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
19. [Chemoprevention of prostate cancer].
Djavan B; Thompson I; Michel MS; Waldert M; Seitz C
Urologe A; 2004 May; 43(5):557-61. PubMed ID: 15042290
[TBL] [Abstract][Full Text] [Related]
20. Prevention strategies for prostate cancer.
Schmitz-Dräger BJ; Lümmen G; Bismarck E; Fischer C
Minerva Urol Nefrol; 2012 Dec; 64(4):225-31. PubMed ID: 23288209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
